SEC Form 4 · accession 0001209191-16-142070
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kamil Ali-Jackson
Officer — Chief Legal Officer
Period of report
Sep 15, 2016
Accepted (ET)
Sep 19, 2016 · 7:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 15, 2016 | J | 50,878 | $0.00 | A | 71,167 | D | |
| Common Stock | Sep 15, 2016 | J | 4,790 | $0.00 | A | 75,957 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Liquidating distribution from NeXeption, LLC, of which the reporting person is a non-managing member, in accordance with NeXeption, LLC's Limited Liability Company Operating Agreement.
- F2Pro rata distribution from NST, LLC, of which the reporting person is a non-managing member, in accordance with NST, LLC's Limited Liability Company Operating Agreement.